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Abstract  79 
Epigenetic processes, including DNA methylation (DNAm), are among the mechanisms 80 
allowing integration of genetic and environmental factors to shape cellular function. While many 81 
studies have investigated either environmental or genetic contributions to DNAm, few have 82 
assessed their integrated effects.  Here we examine the relative contributions of prenatal 83 
environmental factors and genotype on DNA methylation in neonatal blood at variably 84 
methylated regions (VMRs) in 4 independent cohorts (overall n=2,365).  85 
We use Akaike’s information criterion to test which factors best explain variability of 86 
methylation in the cohort-specific VMRs: several prenatal environmental factors (E), genotypes 87 
in cis (G), or their additive (G+E) or interaction (GxE) effects.  88 
Genetic and environmental factors in combination best explain DNAm at the majority of VMRs. 89 
The CpGs best explained by either G, G+E or GxE are functionally distinct. The enrichment of 90 
genetic variants from GxE models in GWAS for complex disorders supports their importance for 91 
disease risk.   92 
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Introduction 93 
Fetal or prenatal programming describes the process by which environmental events during 94 
pregnancy influence the development of the embryo with on-going implications for future health 95 
and disease. Several studies have shown that the in utero environment is associated with disease 96 
risk, including coronary heart disease 1,2, type 2 diabetes 3, childhood obesity 4,5 as well as 97 
psychiatric problems 6 and disorders 7-9. 98 
Environmental effects on the epigenome, for example via DNA methylation, could lead to 99 
sustained changes in gene transcription and thus provide a molecular mechanism for the 100 
enduring influences of the early environment on later health 10. Smoking during pregnancy 101 
influences widespread and highly reproducible differences in DNA methylation at birth 11. Less 102 
dramatic effects have been reported for maternal body mass index (BMI) 12, pre-eclampsia and 103 
gestational diabetes 13,14.  Possible epigenetic changes as a consequence of prenatal stress are less 104 
well established 15. Some of these early differences in DNA methylation persist, although 105 
attenuated, through childhood 11,16 and might be related to later symptoms and indicators of 106 
disease risk, including BMI during childhood 17,18 or substance use in adolescence 19. These data 107 
emphasize the potential importance of the prenatal environment for the establishment of inter-108 
individual variation in the methylome as a predictor or even mediator of disease risk trajectories.  109 
In addition to the environment, the genome plays an important role in the regulation of DNA 110 
methylation. To this end, the impact of genetic variation, especially of single nucleotide 111 
polymorphisms (SNPs) on DNA methylation in different tissues, has resulted in the discovery of 112 
a large number of methylation quantitative trait loci (meQTLs, i.e., SNPs significantly associated 113 
with DNA methylation status 20). These variants are primarily in cis, i.e., at most 1 million base 114 
pairs away from the DNA methylation site 20-22 and often co-occur with expression QTLs or 115 
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other regulatory QTLs 23-25. The association of meQTLs with DNA methylation is relatively 116 
stable throughout the life course 21. In addition, SNPs within meQTLs are strongly enriched for 117 
genetic variants associated with common disease in large genome-wide association studies 118 
(GWAS) such as BMI, inflammatory bowel disease, type 2 diabetes or major depressive disorder 119 
21,23,24,26. 120 
Environmental and genetic factors may act in an additive or multiplicative manner to shape the 121 
epigenome to modulate phenotype presentation and disease risk 27. However, very few studies 122 
have so far investigated the joint effects of environment and genotype on DNA methylation, 123 
especially in a genome-wide context. Klengel et al. 28 , for instance, reported an interaction of the 124 
FK506 binding protein 5 gene (FKBP5) SNP genotype and childhood trauma on FKBP5 125 
methylation levels in peripheral blood cells, with trauma associated changes only observed in 126 
carriers of the rare allele. The most comprehensive study of integrated genetic and environmental 127 
contributions to DNA methylation so far was performed by Teh et al. 29. This study examined 128 
variably methylated regions (VMRs), defined as regions of consecutive CpG-sites showing the 129 
highest variability across all methylation sites assessed on the Illumina Infinium 130 
HumanMethylation450 BeadChip array. In a study of 237 neonate methylomes derived from 131 
umbilical cord tissue, the authors explored the proportions of the influence of genotype vs. 132 
prenatal environmental factors such as maternal BMI, maternal glucose tolerance and maternal 133 
smoking on DNA methylation at VMRs. They found that 75% of the VMRs were best explained 134 
by the interaction between genotype and environmental factors (GxE) whereas 25% were best 135 
explained by SNP genotype and none by environmental factors alone. Collectively, these studies 136 
highlight the importance of investigating the combination of environmental and genetic 137 
contributions to DNA methylation and not only their individual contribution.  138 
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The main objective of the present study is to extend our knowledge of combined effects of 139 
prenatal environment and genetic factors on DNA methylation at VMRs. Specifically, this is 140 
addressed by: 1) assessing the stability of the best explanatory factors across different cohorts 141 
and whether this extends to all environmental factors, 2) dissecting differences between additive 142 
and interactive effects of gene and environment not explored in Teh et al., 3) testing whether 143 
VMRs influenced by genetic and/or environmental factors might have a different predicted 144 
impact on gene regulation and 4) evaluating the relevance of genetic variants that interact with 145 
the environment to shape the methylome for their contribution to genetic disease risk.  146 
Our results show that across cohorts genetic variants in combination with prenatal environment 147 
are the best predictors of variance in DNA methylation. We observe functional differences of 148 
both the genetic variants and the methylation sites best explained by genetic or additive and 149 
interactive effects of genes and environment. Finally, the enrichment of genetic variants within 150 
additive as well as interactive models in GWAS for complex disorders supports the importance 151 
of these environmentally modified methylation quantitative trait loci for disease risk. 152 
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Results   153 
Cohorts and analysis plan 154 
We investigated the influence of the prenatal environment and genotype on VMRs in the DNA 155 
of 2,365 newborns within 4 different cohorts: Prediction and Prevention of Pre-eclampsia and 156 
Intrauterine Growth Restrictions (PREDO, cordblood) 30, the UCI cohort (31-33, heel prick), the 157 
Drakenstein Child Health Study (DCHS, cordblood) 34,35 and the Norwegian Mother and Child 158 
Cohort Study (MoBa, cordblood 36). A description of the workflow of this manuscript is given in 159 
Figure 1 and the details for each of the cohorts are given in Table 1.  160 
Table 1: overview of investigated cohorts 161 
cohort PREDO I PREDO II DCHS I DCHS II UCI MoBa 
sample-size 817 146 107 151 121 1,023 
methylation array Illumina 
450K 
Illumina 
EPIC 
Illumina 
450K 
Illumina 
EPIC 
Illumina 
EPIC 
Illumina  
450K 
Methylation data 
processing 
Funnorm 
and 
Combat 
Funnorm 
and Combat 
SWAN and 
Combat 
BMIQ and 
Combat 
Funnorm 
and 
Combat  
BMIQ and  
Combat 
SNP genotyping Illumina 
Human 
Omni 
Express 
Exome 
 
Illumina 
Human 
Omni 
Express 
Exome 
 
Illumina 
PsychArray 
Illumina 
GSA 
Illumina 
Human 
Omni 
Express 
Illumina 
HumanExo
me 
Core 
infant gender 
male 
433 
(53.0%) 
75 (51.4%) 63 (58.8%) 83 
(55.0%) 
65 
(53.7%) 
478 (46.7%)
maternal age mean (sd) 33.28 
(5.79) 
32.25 (4.92) 26.27 (5.87) 27.42 
(5.93) 
28.47 
(4.91) 
29.92 (4.32) 
partity mean (sd) 1.05 (1.02) 0.87 (1.03) 0.98 (1.12) 1.09 
(1.07) 
1.11 
(1.15) 
0.83 (0.88) 
Caesarian section  169 
(20.7%) 
36 (24.7%) 19 (17.6%) 35 
(23.2%) 
37 
(30.6%) 
228 (22.3%)
pre-pregnancy BMI 
mean (sd) 
27.42 
(6.40) 
25.37 (5.79) not 
available 
not 
available 
27.90 
(6.44) 
24.05 (4.19) 
maternal smoking yes exclusion 
criterion 
exclusion 
criterion 
7.40 (10.52) 
a) 
4.94 
(9.43) a) 
10 
(8.2%) 
148 (14.4%) 
gestational diabetes yes 183 
(22.4%) 
19 (13.0%) no cases 
available 
no cases 
available 
9 (7.4%) 15 (1.5%) 
hypertension yes 275 31 (21.2%) 2 (.19%) 2 (1.3%) 7 (5.8%) 50 (4.9%) 
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(33.7%) 
betamethasone 
treatment yes 
35 (4.3%) 2 (1.5%) not 
available 
not 
available 
no cases 
available 
not  
available 
anxiety score mean (sd) 33.93 
(7.90) b) 
34.43 (8.38) 
b) 
5.70 (4.15) 
c) 
5.32 
(3.91) c) 
1.67 
(0.41) d) 
4.79 (1.36) 
e) 
depression score mean 
(sd) 
11.34 
(6.47) f) 
11.53 (6.98) 
f) 
17.64 
(12.10) g)   
12.52 
(11.55) g)   
0.68 
(0.41) h)    
5.24 (1.57) 
e) 
a) based on ASSIST Tobacco Score  162 
b) STAI sum scores 163 
c) SRQ-20 164 
d)  STAI average scores 165 
e)  based on Hopkins Symptom Checklist 166 
 f)  CESD sum scores 167 
g)  BDI-II 168 
h) CESD average score 169 
 170 
 171 
We analyzed 963 cord blood samples from the PREDO cohort with available genome-wide DNA 172 
methylation and genotype data. Of these samples, 817 had data on the Illumina 450k array 173 
(PREDO I) and 146 on the Illumina EPIC array (PREDO II). The main analyses are reported for 174 
PREDO I, and replication and extension of the results is shown for PREDO II as well as for three 175 
independent cohorts including 121 heel prick samples (UCI cohort, EPIC array) as well as 258 176 
(DCHS, 450K and EPIC array) and 1,023 cord blood samples (MoBa, 450K array). We tested 177 
ten different prenatal environmental factors covering a broad spectrum of prenatal phenotypes 178 
(see Table 1) (referred to as E), as well as cis SNP genotype (referred to as G), i.e., SNPs located 179 
in at most 1MB distance to the specific CpG, additive effects of cis SNP genotype and prenatal 180 
environment (G+E) and cis SNP x environment interactions (GxE) for association with DNA 181 
methylation levels (see Figure 1). We then assessed for each VMR independently which model 182 
described the variance of DNAm best using Akaike’s information criterion (AIC) 37. In all 183 
models, we corrected for child’s gender, ethnicity (using MDS-components), gestational age as 184 
well as estimated cell proportions to account for cellular heterogeneity.  185 
 186 
Variably Methylated Regions  187 
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We first identified candidate VMRs, defined as regions of CpG-sites showing the highest 188 
variability across all methylation sites. In PREDO I, we identified 10,452 variable CpGs that 189 
clustered into 3,982 VMRs (see Supplementary Data 1). Most VMRs (n=2,683) include 2 CpGs. 190 
As detailed in Supplementay Note 1, the distribution of methylation levels of CpGs within these 191 
VMRs is unimodal, (see Supplementary Figure 1A), VMRs are enriched in specific functional 192 
regions of the genome, correlate with differences in gene expression, and overlap with sites 193 
associated with specific prenatal environmental factors.  194 
To examine the factors that best explain the variance in methylation in these functionally 195 
relevant sites, we chose the CpG-site with the highest MAD-score as representative of the VMR. 196 
These CpGs are named tagCpGs. The correlation between methylation levels of tagCpG and 197 
average methylation of the respective VMR was high (mean r=0.85, sd r=0.08), suggesting that 198 
the tag CpGs are valid representatives of their VMRs. Furthermore, tagCpGs are mainly 199 
uncorrelated with each other (mean r=0.03, sd=0.12). 200 
 201 
Which models explain methylation of tagCpGs best? 202 
We next compared the fit of four models for each of the 3,982 tagCpGs (see Figure 1): best SNP 203 
(G model), best environment (E model), SNP + environment (G+E model) and SNP x 204 
environment (GxE model). Association results for each model are listed in Supplementary Data 205 
2-5. For each tagCpG, the model with the lowest AIC was chosen as the best model (see 206 
Methods section).  In total, 40.6% of tagCpGs were best explained by GxE (n=1,616), followed 207 
by G (30%, n=1, 194) and G+E (29%, n=1,171) (Figure 2A). E explained most variance in one 208 
tagCpG. All tag CpGs and the respective SNPs and environments from the best model are listed 209 
in Supplementary Data 6-8 and Supplementary Table 1.  210 
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With regard to environmental factors, 27.0% of tagCpGs best explained by the G+E model were 211 
associated with environmental factors related with stress or, in particular, glucocorticoids (i.e., 212 
maternal betamethasone treatment), 40.8% with general maternal factors (mostly maternal age) 213 
and 32.20 % with factors related to metabolism (pre-pregnancy BMI, hypertension, gestational 214 
diabetes). For best model GxE tagCpGs, the proportions of environmental factors were similar 215 
with 22.2%, 44.1% and 33.7%, respectively (see Figure 2B). 216 
We next looked into the delta AIC, i.e., the difference between the AIC of the best model to the 217 
AIC of the next best model (see Supplementary Note 2). GxE models appear to be winning by a 218 
significantly larger AIC margin over the next best model, when compared to the other types of 219 
winning models (see Figure 2C). 220 
 221 
DeepSEA prediction of SNP function 222 
We were next interested in understanding the functionality of both the VMRs as well as the 223 
associated SNPs in the G, GxE and G+E models. For this we restricted the analyses only to 224 
potentially functional relevant SNPs using DeepSEA 38 and not all linkage disequilibrium (LD)-225 
pruned SNPs as described above. DeepSEA, a deep neural network pretrained with DNase-seq 226 
and ChIP-seq data from the ENCODE 39 project, predicts the presence of histone marks, DNase 227 
hypersensitive regions (DHS) or TF binding for a given 1kb sequence. The likelihood that a 228 
specific genetic variant influences regulatory chromatin features is estimated by comparing 229 
predicted probabilities of two sequences where the bases at the central position are the reference 230 
and alternative alleles of a given variant.  We reran the four models now restricting the cis-SNPs 231 
to those 36,241 predicted DeepSEA variants that were available in our imputed, quality-232 
controlled genotype dataset. 233 
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Top results for models including G, GxE and G+E are depicted in Supplementary Data 9-12.  234 
Results were comparable to what we observed before:  1,195 (30.09%) of tagCpGs presented 235 
with best model G, 1,193 CpGs (30.04%) with best model G+E, 1,510 CpGs (38.02 %) with best 236 
model GxE and 74 CpGs (1.86%) with best model E (Figure 3A) and also showed similar 237 
differences in delta-AIC and proportions of E categories (see Supplementary Note 3). Only 10 238 
tagCpGs did not present with any DeepSEA variant within 1MB distance in cis and were 239 
therefore not further considered. All respective CpG-environment-DeepSea SNP-combinations 240 
are depicted in Supplementary Data13-16.  241 
The distribution of best models was not influenced by the degree of variability of DNA 242 
methylation, but was comparable across the whole range of DNA methylation variation (see 243 
Supplementary Note 4 and Supplementary Figure 2). A slight enrichment for G+E models was 244 
observed in longer VMRs with at least 3 CpGs (p=9.00 x 10-06, OR=1.39, Fisher-test, see 245 
Supplementary Figure 3). 246 
In conclusion, also when we focus on potentially functionally relevant SNPs, it is the 247 
combination of genotype and environment which best explains VMRs.  248 
We observed that, as expected, different types of exposures or maternal factors have different 249 
relative impact on DNA methylation (see Supplementary Note 5). However, even for those 250 
exposures with the highest fraction of VMRs best explained by E alone, combined models of 251 
G+E and GxE remain the best models in even higher fractions of VMRs (see Supplementary 252 
Figure 4B). 253 
 254 
Functional annotation of different best models 255 
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Focusing on combinations between tagCpGs, environmental factors and DeepSEA variants, we 256 
found functional differences for both the SNPs as well as the tagCpGs (see Supplementary Note 257 
6) within the different models. Overall, 895 DeepSEA variants were uniquely involved in best G 258 
models, 905 were uniquely in best G+E models and 1,162 uniquely in best GxE models. As a 259 
DeepSEA variant can be in multiple 1 MB-cis windows around the tagCpGs, several DeepSEA 260 
variants were involved in multiple best models: 138 DeepSEA variants overlapped between G 261 
and GxE, 118 between G and G+E and 147 between GxE and G+E VMRs. We observed no 262 
significant differences with regard to gene-centric location for DeepSEA variants involved only 263 
in G models, only in G+E models or in multiple models. However, DeepSEA variants involved 264 
only in GxE models were significantly depleted for promoter locations (p=3.92 x 10-02, 265 
OR=0.79, Fisher-test, see Supplementary Figure 5A).   266 
Although no significant differences were present, DeepSEA SNPs involved in the G and G+E 267 
model were located in closer proximity to the specific CpG (model G: mean absolute 268 
distance=256.8 kb, sd=291.2 kb, model G+E: mean absolute distance =244.8 kb, sd=284.0 kb, 269 
Supplementary Figure 5B) whereas DeepSEA SNPs involved in GxE models (mean absolute 270 
distance =352.6 kb, sd=305.3 kb) showed broader peaks around the CpGs.  271 
With regards to histone marks, DeepSEA variants in general were enriched across multiple 272 
histone marks indicative of active transcriptional regulation (Figure 4C).  DeepSEA variants 273 
involved in best model G+E showed further enrichment for strong transcription (p=7.19x10-03, 274 
OR=1.34, Fisher-test) as well as depletion for quiescent loci (p=7.17x10-03, OR=0.78, Fisher-275 
test). In contrast, GxE DeepSEA variants were significantly enriched in these regions 276 
(p=2.62x10-02, OR=1.22, Fisher-test, Figure 4D). 277 
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Taken together, these analyses indicate that both the genetic variants and the VMRs in the 278 
different best models (G, GxE and G+E) preferentially annotate to functionally distinct genomics 279 
regions. 280 
 281 
Replication of best models in independent cohorts 282 
To assess whether the relative distribution of the best models for VMRs and DeepSEA variants 283 
was stable across different samples, we assessed the relative distribution of these models in 3 284 
additional samples (DCHS I and DCHS II, UCI and PREDOII) with VMR data both from the 285 
Illumina 450K as well as the IlluminaHumanEPIC arrays. Information on these cohorts is 286 
summarized in Table 1 and the number of VMRs, the distribution of VMR methylation levels, 287 
VMR length and specific SNP information are given in Supplementary Note 7 and 288 
Supplementary Figure 6.  289 
While major maternal factors overlapped among the cohorts - such as maternal age, delivery 290 
method, parity and depression during pregnancy - there were also differences, as the non-291 
PREDO cohorts did not include betamethasone treatment but additionally included maternal 292 
smoking (see Table 1). Despites these differences and differences in the total number of VMRs, 293 
the overall pattern remained stable: in all 4 analyses, DCHS I, DCHS II, UCI and PREDO II, we 294 
replicated that E alone models almost never explained most of the variances, while G alone 295 
models explained the most variance in up to 15% of the VMRs; G+E in up to 32%; and GxE 296 
models in up to 60% (see Figure 5 and Table 2).  297 
 298 
Table 2: VMRs and best models across cohorts 299 
cohort PREDO I PREDO II DCHS I DCHS II UCI 
sample-size 817 146 107 151 121 
methylation array Illumina 450K Illumina EPIC Illumina 450K Illumina EPIC Illumina EPIC 
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# VMRs 3,972 8,547 6,072 10,005 9,525 
proportion: 
best model E 
 
2.0% 
 
<1% 
 
<1% 
 
<1% 
 
4.1% 
best model G 30.0% 15.0% 15.8% 11.5% 12.8% 
best model G+E 30.0% 29.0% 29.8% 32.1% 24.1% 
best model GxE 38.0% 56.0% 54.3% 56.3% 59.0% 
 300 
The importance of including G for a best model fit could also be observed for maternal smoking, 301 
described as one of the most highly replicated factors shaping the newborns’ methylome 11 and 302 
present in the replication but not the discovery cohort PREDO I. These analyses are detailed in 303 
Supplementary Note 8.  304 
We were also able to replicate our finding showing that GxE VMRs were enriched for OpenSea 305 
positions with a trend on the 450K array (DCHS I, OR=1.11, p= 5.03x10-02, Fisher-test) and 306 
significantly for the EPIC array data (PREDOII: p=2.96x10-06, OR=1.29, UCI: p= 3.79x10-02, 307 
OR=1.09, DCHSII: p=2.91x10-04, OR=1.16, Fisher-tests).  For all additional cohorts, the delta 308 
AIC for best model GxE to the next best model was also significantly higher as compared to 309 
CpGs with G, E or G+E as the best model.   310 
Overall, 387 tag CpGs overlapped between PREDO I, PREDO II, DCHS I and DCHS II (see 311 
Supplementary Figure 7), which allowed us to test the consistency of the best models for specific 312 
VMRs across the different cohorts. Over 70% of the overlapping tagCPGs showed consistent 313 
best models in at least 3 cohorts (see Figure 6) with GxE being the most consistent model (for 314 
over 60% of consistent models, see Supplementary Figure 8). Focusing only on EPIC data 315 
(PREDO II, DCHSII and UCI), we identified more, namely 2,091, tag CpGs that overlap across 316 
the three cohorts and here 86% show a consistent best model in at least two of the three cohorts, 317 
despite differences in study design, prenatal phenotypes and ethnicity. 318 
Thus, the additional cohorts not only showed a consistent replication of the proportion of the 319 
models best explaining variance of VMRs but also consistency of the best model for specific 320 
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VMRs. Within this context, we observed the GxE models were the most consistent models 321 
across the cohorts (, see Supplementary Figure 8), with 85% of the CpGs with consistent models 322 
across 5 cohorts having GxE as the best model. Furthermore, we could validate specific GxE 323 
combinations between PREDO I and MoBa as shown as in the Supplementary Note 9.  324 
 325 
Disease relevance 326 
Finally, we tested whether functional DeepSEA SNPs involved in only G, only GxE and only 327 
G+E models in PREDO I for their enrichment in GWAS hits. We used all functional SNPs and 328 
their LD proxies (defined as r2 of at least 0.8 in the PREDO cohort and in maximal distance of 329 
1MB to the target SNP) and performed enrichment analysis with the overlap of nominal 330 
significant GWAS hits. We selected for a broad spectrum of GWAS, including GWAS for 331 
complex disorders for which differences in prenatal environment are established as risk factors, 332 
but also including GWAS on other complex diseases. For psychiatric disorders, we used 333 
summary statistics of the Psychiatric Genomics Consortium (PGC) including association studies 334 
for autism 40, attention-deficit-hyperactivity disorder 41, bipolar disorder 42, major depressive 335 
disorder 43, schizophrenia 44 and the cross-disorder associations including all five of these 336 
disorders 45. Additionally, we included GWAS of inflammatory bowel disease 46, type 2 diabetes 337 
47 and for BMI 48. Nominal significant GWAS findings were enriched for DeepSEA variants and 338 
their LD proxies per se across psychiatric as well as non-psychiatric diseases (Figure 7A). 339 
However, G, GxE and G+E DeepSEA variants showed a differential enrichment pattern above 340 
all DeepSEA variants (Figure 7B), with strongest enrichments of GxE DeepSEA variants in 341 
GWAS of autism spectrum disorder (p<2.20 x 10-16,OR=2.07 above DeepSEA, Fisher-test), 342 
attention-deficit-hyperactivity disorder (p<2.20 x 10-16, OR=1.71, Fisher-test) and inflammatory 343 
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bowel disease ( p<2.20 x 10-16, OR=1.71, Fisher-test) and G+E DeepSEA variants in GWAS for 344 
attention-deficit-hyperactivity disorder (p=9.54x10-36, OR=1.23, Fisher-test) and inflammatory 345 
bowel disease (p=1.85x10-52, OR=1.30, Fisher-test). While SNPs with strong main meQTL 346 
effects such as those within G and G+E models have been reported to be enriched in GWAS for 347 
common disease, we now also show this for SNPs within GxE models that often have non-348 
significant main G effects.  349 
 350 
Discussion 351 
We evaluated the effects of prenatal environmental factors and genotype on DNA methylation at 352 
VMRs identified in neonatal blood samples. We found that most variable methylation sites were 353 
best explained by either genotype and prenatal environment interactions (GxE) or additive 354 
effects (G+E) of these factors, followed by main genotype effects. This pattern was replicated in 355 
independent cohorts and underscores the need to consider genotype in the study of 356 
environmental effects on DNA methylation.  357 
In fact, VMRs best explained by G, G+E or GxE and their associated functional genetic variants 358 
were located in distinct genomic regions, suggesting that different combinatorial effects of G and 359 
E may impact VMRs with distinct downstream regulatory effects and thus possibly context-360 
dependent impact on cellular function. We also observed that functional variants with best 361 
models G, G+E or GxE, all showed significant enrichment within GWAS signals for complex 362 
disorders beyond the enrichment of the functional variants themselves. While this was expected 363 
for G and G+E models based on results from previous studies 21,23,24,26, it was surprising for GxE 364 
SNPs, as these often do not have highly significant main genetic effects. Their specific 365 
enrichment in GWAS for common disorders supports the importance of these genetic variants 366 
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that moderate environmental impact both at the level of DNA methylation but also, potentially, 367 
for disease risk. 368 
The fact that GxE and G+E best explained the majority of VMRs (see Figure 5) and that GxE 369 
models were selected by a larger margin than the other models (see Figure 2C) was consistently 370 
found across all tested cohorts. These findings are in line with a previous report by Teh et al. 29 371 
who performed a similar analysis based on AIC in umbilical cord tissue. Differences to the 372 
findings by Teh et al. are discussed in the Supplemental Discussion. Using data from 4 different 373 
cohorts, we not only saw comparable proportions of VMRs best explained by the different 374 
models, but also saw in the VMRs common across cohorts that specific VMRs had consistent 375 
best models (see Figure 6). This is in line with the fact that VMRs best explained by G, GxE or 376 
G+E show functional differences and may differentially impact gene regulation. 377 
In addition to consistent findings using AIC-based approaches, we also observed some indication 378 
for validation of individual GxE and G+E combinations on selected VMRs using p-value based 379 
criteria, with a small number of specific G+E and GxE effects on VMRs replicating between the 380 
PREDO I and the MoBa cohort. The low number of specific replications could be due to lack of 381 
overall power as well as larger differences in prenatal factors between these two cohorts (see 382 
Table 1). As shown in Supplementary Figure 4B, which specific G and E combinations best 383 
explain VMRs is also dependent on the specific prenatal factors. Larger and more homogenous 384 
cohorts regarding exposures will be needed for such analyses to be more conclusive. 385 
While E alone was rarely the best model, it should be pointed out that main environmental 386 
effects on DNA methylation were observed (see Supplementary Data 3), and consistent with 387 
previous large meta-analyses such as in the case of maternal smoking (see Supplementary Notes 388 
7). Within the MoBa cohort, the cohort with the largest proportion of maternal smoking, 10% of 389 
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all tagCpGs were best explained by maternal smoking alone. However, in all other cohorts, 390 
where smoking was less prevalent, the inclusion of genotypic effects in addition to maternal 391 
smoking explained more of the variance. This supports that while main E effects on the newborn 392 
methylome are present, genotype is an important factor that, in combination with E, may explain 393 
even more of the variance in DNA methylation.  394 
VMRs best explained by either E, G, G+E or GxE and their associated functional SNPs were 395 
enriched for distinct genomics locations and chromatin states (see Figure 4), suggesting that 396 
VMRs moderated by different combinations of G and E may in fact have distinct functional roles 397 
in gene regulation. Overall, VMRs best explained by GxE were consistently enriched for regions 398 
annotated to the OpenSea regions with lower CpG density and located farthest from CpG Islands 399 
49. Open Sea regions have been reported to be enriched for environmentally-associated CpGs 400 
with for example exposure to childhood trauma 50 and may harbor more long-range enhancers.  401 
In addition to their position relative to CpG islands and their CpG content, G, GxE and G+E 402 
VMRs and their associated functional SNPs also showed distinct enrichments for chromatin 403 
marks. Compared to 450K VMRs in general, VMRs with GxE as the best models were relatively 404 
depleted in regions surrounding the TSS, while VMRs with G+E were relatively enriched in 405 
these regions (see Figure 4), suggesting that GxE VMRs are located at more distance from the 406 
TSS than G+E VMRs. To better map the potential functional variants in these models and to 407 
compare methylation-associated SNPs from a regulatory perspective, we used DeepSEA 38, a 408 
machine learning algorithm that predicts SNP functionality from the sequence context based on 409 
sequencing data for different regulatory elements in different cell lines using ENCODE data 39. 410 
We identified the SNPs with putatively functional consequences on regulatory marks by 411 
DeepSEA and compared putative regulatory effects of G, G+E and GxE hits. Relative to the 412 
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imputed non-DeepSEA SNPs contained in our dataset, these predicted functional DeepSEA 413 
SNPs were enriched for TSS and enhancer regions and depleted for quiescent regions, supporting 414 
their relevance in regulatory processes (see Figure 4). Compared to DeepSEA SNPs overall, 415 
DeepSEA SNPs within the 3 different best models also showed distinct enrichment or depletion 416 
patterns. Similar to GxE VMRs, likely functional GxE SNPs also showed a relative depletion in 417 
TSS regions while G+E SNPs showed enrichment in genic enhancers. Overall, both the VMRs 418 
as well as the associated functional SNPs appear to be in distinct regulatory regions, depending 419 
on their best model. In addition, GxE functional SNP and tagCpGs were located farther apart 420 
than SNP/tagCpG pairs within G or G+E models (see Supplementary Figure 5B), supporting a 421 
more long-range type of regulation in GxE interactions on molecular traits as compared to all 422 
genes; a similar relationship has been reported previously for GxE with regard to gene 423 
expression in C. elegans 51,52.  424 
SNPs associated with differences in gene expression but also DNA methylation have consistently 425 
been shown to be enriched among SNPs associated with common disorders in GWAS 21,24,26,53. 426 
The functional genetic variants that were within G, GxE or G+E models predicting variable 427 
DNA methylation were even enriched in GWAS association results (beyond the baseline 428 
enrichment of DeepSea SNPs per se). The fact that such enrichment was observed for not only G 429 
and G+E SNPs, with strong main genetic effects, but also for GxE SNPs, with smaller to 430 
sometimes no main genetic effect on DNA methylation underscores the importance of also 431 
including SNPs within GxE models in the functional annotation of GWAS. A detailed catalogue 432 
of meQTLs that are responsive to environmental factors could support a better 433 
pathophysiological understanding of diseases for which risk is shaped by a combination of 434 
environment and genetic factors.  435 
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Finally, we want to note the limitations of this study. First, we restricted our analyses to specific 436 
DNA methylation array contents that are inherently biased as compared to genome-wide bisulfite 437 
sequencing, for example.  In addition, we restricted our analysis to VMRs, which also limits the 438 
generalizability of the findings, but also has advantages. Ong and Holbrooke 54 showed that this 439 
approach increases statistical power. Furthermore, VMRs are enriched for enhancers and 440 
transcription factor binding sites, overlap with GWAS hits 55 and are associated with gene-441 
expression of nearby genes at these sites 56. VMRs in this study presented with intermediate 442 
methylation levels which have been shown to be enriched in regions of regulatory function, like 443 
enhancers, exons and DNase I hypersensitivity sites 57.  Hence, the effects of genotypes on 444 
DNA methylation levels in VMRs might be higher as compared to less variable CpG-sites. In 445 
addition, genotypes are measured with much less error as compared to environmental factors 446 
which may also reduce the overall explained variance in large cohorts. 447 
Second, it has been reported that different cell types display different patterns of DNA 448 
methylation 55. Therefore, the most variable CpG-sites may also include those that reflect 449 
differences in cord blood cell type proportions. To address this issue, all analyses were corrected 450 
for estimated cell proportions to the best of our current availability, so that differences in cell 451 
type proportion likely do not account for all of the observed effects.  However, only replication 452 
in specific cell types will be able to truly assess the proportion of VMRs influenced by this.  453 
Third, we used the AIC as main criterion for model fit 37 which is equivalent to a penalized 454 
likelihood-function. There are a variety of other model selection criteria 58 and choosing between 455 
these is an ongoing debate which also depends on the underlying research question.  We decided 456 
to use the AIC as one of our main aims was to compare our results with the study of Teh et al. 29 457 
 
 
21 
in which this criterion was applied and as this method maybe more powerful for detecting GxE 458 
than for example model selection criteria based on lowest p-values.   459 
Fourth, all reported interactions are statistical interactions and limited to a cis window around the 460 
CpG-site. Further experiments are required to assess whether these would also reflect 461 
biological/mechanistic interactions. Much larger cohorts will be needed to assess potential trans 462 
effects. Additional inclusion of further covariates such as maternal smoking or maternal age may 463 
further modify the effects of specific Es but is beyond the scope of this manuscript. 464 
Fifth, as summarized in Table 1, results presented are based on cohorts which differ in ethnicity, 465 
assessed phenotypes, methylation and SNP arrays, processing pipelines and sample sizes. While 466 
all these factors may contribute to differences in the proportions of models across the cohorts, it 467 
also suggests that our findings are quite robust to these methodological issues. 468 
Finally, our analyses are restricted to DNA methylation in neonatal blood and to pregnancy 469 
environments. Whether similar conclusions can be drawn for methylation levels assessed at a 470 
later developmental stage needs to be investigated.   471 
We tested whether genotype, a combination of different prenatal environmental factors and the 472 
additive or the multiplicative interactive effects of both mainly influence VMRs in the newborn’s 473 
epigenome. Our results show that G in combination with E are the best predictors of variance in 474 
DNA methylation. This highlights the importance of including both individual genetic 475 
differences as well as environmental phenotypes into epigenetic studies and also the importance 476 
of improving our ability to identify environmental associations. Our data also support the disease 477 
relevance of variants predicting DNA methylation together with the environment beyond main 478 
meQTL effects, and the view that there are functional differences of additive and interactive 479 
effects of genes and environment on DNA methylation. Improved understanding of these 480 
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functional differences may also yield novel insights into pathophysiological mechanisms of 481 
common non-communicable diseases, as risk for all of these disorders is driven by both genetic 482 
and environmental factors. 483 
 484 
Methods 485 
 486 
The PREDO cohort  487 
The Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) 488 
Study is a longitudinal multicenter pregnancy cohort study of Finnish women and their singleton 489 
children born alive between 2006-2010 30. We recruited 1,079 pregnant women, of whom 969 490 
had one or more and 110 had none of the known clinical risk factors for preeclampsia and 491 
intrauterine growth restriction. The recruitment took place when these women attended the first 492 
ultrasound screening at 12+0-13+6 weeks+days of gestation in one of the ten hospital maternity 493 
clinics participating in the study. The cohort profile 30 contains details of the study design and 494 
inclusion criteria. 495 
Ethics 496 
The study protocol was approved by the Ethical Committees of the Helsinki and Uusimaa 497 
Hospital District and by the participating hospitals. A written informed consent was obtained 498 
from all women.  499 
Maternal characteristics 500 
We tested 10 different maternal environments: 501 
Depressive symptoms 502 
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Starting from 12+0-13+6 gestational weeks+days pregnant women filled in the 20 item Center 503 
for Epidemiological Studies Depression Scale (CES-D) 59 for depressive symptoms in the past 7 504 
days. They filled in the CES-D scale biweekly until 38+0-39+6 weeks+days of gestation or 505 
delivery. We used the mean-value across all the CES-D measurements. 506 
Symptoms of anxiety 507 
At 12+0-13+6 weeks+days of gestation, women filled in the 20 item Spielberger's State Trait 508 
Anxiety Inventory (STAI) 60 for anxiety symptoms in the past 7 days. They filled in the STAI 509 
scale biweekly until 38+0-39+6 weeks+days of gestation or delivery. We used the mean-value 510 
across all these measurements. 511 
Betamethasone 512 
Antenatal betamethasone treatment (yes/no) was derived from the hospital records and the 513 
Finnish Medical Birth Register (MBR). 514 
Delivery method 515 
Mode of delivery (vaginal delivery vs. caesarean section) was derived from patient records and 516 
MBR. 517 
Parity 518 
Parity (number of previous pregnancies leading to childbirth) at the start of present pregnancy 519 
was derived from the hospital records and the MBR. 520 
Maternal age 521 
Maternal age at delivery (years) was derived from the hospital records and the MBR. 522 
Pre-pregnancy BMI 523 
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Maternal pre-pregnancy BMI (kg/m2), calculated from measurements weight and height verified 524 
at the first antenatal clinic visit at 8+4 (SD 1+3) gestational week was derived from the hospital 525 
records and the MBR. 526 
Hypertension 527 
Hypertension was defined as any hypertensive disorder including gestational hypertension, 528 
chronic hypertension and preeclampsia against normotension. Gestational hypertension was 529 
defined as systolic/diastolic blood pressure ≥140/90 mm Hg on ≥ 2 occasions at least 4 h apart in 530 
a woman who was normotensive before 20th week of gestation. Preeclampsia was defined as 531 
systolic/diastolic blood pressure ≥140/90 mm Hg on ≥2 occasions at least 4 h apart after 20th 532 
week of gestation and proteinuria ≥300 mg/24 h. Chronic hypertension was defined as 533 
systolic/diastolic blood pressure ≥140/90 mm Hg on ≥2 occasions at least 4 h apart before 20th 534 
gestational week or medication for hypertension before 20 weeks of gestation.  535 
Gestational diabetes and oral glucose tolerance test (OGTT) 536 
Gestational diabetes was defined as fasting, 1h or 2h plasma glucose during a 75g oral glucose 537 
tolerance test ≥5.1, ≥10.0 and/or ≥8.5 mmol/L, respectively, that emerged or was first identified 538 
during pregnancy. We took the area under the curve from the three measurements as a single 539 
measure for the OGTT itself. 540 
Genotyping and Imputation 541 
Genotyping was performed on Illumina Human Omni Express Exome Arrays containing 964,193 542 
SNPs.  Only markers with a call rate of at least 98%, a minor allele frequency of at least 1% and 543 
a p-value for deviation from Hardy-Weinberg-Equilibrium > 1.0 x 10-06 were kept in the 544 
analysis. After QC, 587,290 SNPs were available. 545 
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In total, 996 cord blood samples were genotyped. Samples with a call rate below 98% (n=11) 546 
were removed.  547 
Any pair of samples with IBD estimates > 0.125 was checked for relatedness. As we corrected 548 
for admixture in our analyses using MDS-components (see Supplemental Figure 10), these 549 
samples were kept except for one pair which could not be resolved. From this pair we excluded 550 
one sample from further analysis. Individuals showing discrepancies between phenotypic and 551 
genotypic sex (n=1) were removed. We also checked for heterozygosity outliers but found none. 552 
983 participants were available in the final dataset. 553 
Before imputation, AT and CG SNPs were removed. Imputation was performed using shapeit2 554 
(https://mathgen.stats.ox.ac.uk./genetics_software/shapeit/shapeit.html) and impute2 555 
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html).  Chromosomal and base pair positions 556 
were updated to the 1000 Genomes Phase 3 reference set, allele strands were flipped where 557 
necessary.  558 
After imputation, we reran quality control, filtering out SNPs with an info score < 0.8, a minor 559 
allele frequency below 1% and a deviation from HWE with a p-value < 1.0x10 -06. 560 
This resulted in a dataset of 9,402,991 SNPs.  After conversion into best guessed genotypes 561 
using a probability threshold of 90%, we performed another round of QC (using SNP-call rate of 562 
least 98%, a MAF of at least 1% and a p-value threshold for HWE of 1.0x10-06), after which 563 
7,314,737 SNPs remained for the analysis.  564 
For the evaluation of which model best explained the methylation sites, we pruned the dataset 565 
using a threshold of r2 of 0.2 and a window-size of 50 SNPs with an overlap of 5 SNPs. The 566 
final, pruned dataset contained 788,156 SNPs. 36,241 of these variants were DeepSea variants 567 
(see Methods below). 568 
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Methylation 569 
Cord blood samples were run on Illumina 450k Methylation arrays. The quality control pipeline 570 
was set up using the R-package minfi 61 (https://www.r-project.org). Three samples were 571 
excluded as they were outliers in the median intensities. Furthermore, 20 samples showed 572 
discordance between phenotypic sex and estimated sex and were excluded.  Nine samples were 573 
contaminated with maternal DNA according to the method suggested by Morin et al. 62 and were 574 
also removed.  575 
Methylation beta-values were normalized using the funnorm function 63. After normalization, 576 
two batches, i.e., slide and well, were significantly associated and were removed iteratively using 577 
the Combat function 64 in the sva package 65. 578 
We excluded any probes on chromosome X or Y, probes containing SNPs and cross-hybridizing 579 
probes according to Chen et al. 53 and Price et al 66. Furthermore, any CpGs with a detection p-580 
value > 0.01 in at least 25% of the samples were excluded.  581 
The final dataset contained 428,619 CpGs and 822 participants. For 817 of these, also genotypes 582 
were available. 583 
An additional 161 cord blood samples were run on Illumina EPIC Methylation arrays. 584 
Three samples were excluded as they were outliers in the median intensities. Three samples 585 
showed discordance between phenotypic sex and estimated sex and were excluded. Three 586 
samples were contaminated with maternal DNA and were also removed 62. 587 
Methylation beta-values were normalized using the funnorm function 63 in the R–package minfi 588 
61. Three samples showed density artefacts after normalization and were removed from further 589 
analysis. We excluded any probes on chromosome X or Y, probes containing SNPs and cross-590 
hybridizing probes according to Chen et al. 53, Price et al. 66 and McCartney et al. 67. 591 
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Furthermore, any CpGs with a detection p-value > 0.01 in at least 25% of the samples were 592 
excluded. The final dataset contains 812,987 CpGs and 149 samples. After normalization no 593 
significant batches were identified. For 146 of these samples, genotypic data was also available. 594 
Cord blood cell counts were estimated for seven cell types (nucleated red blood cells, 595 
granulocytes, monocytes, natural killer cells, B cells, CD4(+)T cells, and CD8(+)T cells) using 596 
the method of Bakulski et al. 68 which is incorporated in the R-package minfi 61. 597 
Identification of VMRs (variable methylated regions) 598 
The VMR approach was described by Ong and Holbrook 54. We chose all 42,862 CpGs with a 599 
MAD score greater than the 90th percentile.  For each CpG-site, the MAD (median absolute 600 
deviation) is defined as the median of the absolute deviations from each individual’s methylation 601 
beta-value at this CpG-site to the CpG’s median. A candidate VMR region was defined as at 602 
least two spatially contiguous probes which were at most 1kb apart of each other.  This resulted 603 
in 3,982 VMRs in the 450K samples and in 8,547 VMRs in the EPIC sample. The CpG with the 604 
highest MAD scores was chosen as representative of the whole VMR in the statistical analysis.  605 
 606 
Drakenstein cohort  607 
Details on this cohort and the assessed phenotypes can be found in 34,35. The birth cohort design 608 
recruits pregnant women attending one of two primary health care clinics in the Drakenstein sub-609 
district of the Cape Winelands, Western Cape, South Africa – Mbekweni (serving a black 610 
African population) and TC Newman (serving a mixed ancestry population). Consenting mothers 611 
were enrolled during pregnancy, and mother–child dyads are followed longitudinally until 612 
children reach at least 5 years of age. Mothers are asked to request that the father of the index 613 
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pregnancy attend a single antenatal study visit where possible. Follow-up visits for mother–child 614 
dyads take place at the two primary health care clinics and at Paarl Hospital.  615 
Pregnant women were eligible to participate if they were 18 years or older, were accessing one 616 
of the two primary health care clinics for antenatal care, had no intention to move out of the 617 
district within the following year, and provided signed written informed consent. Participants 618 
were enrolled between 20 and 28 weeks’ gestation, upon presenting for antenatal care visit.  In 619 
addition, consenting fathers of the index pregnancy when available were enrolled in the study 620 
and attended a single antenatal study visit.  621 
Ethics 622 
The study was approved by the Faculty of Health Sciences, Human Research Ethics Committee, 623 
University of Cape Town (401/2009), by Stellenbosch University (N12/02/0002), and by the 624 
Western Cape Provincial Health Research committee (2011RP45). All participants provided 625 
written informed consent.                                                                                    626 
Maternal characteristics                                                                                                        627 
After providing consent, participants were asked to complete a battery of self-report and 628 
clinician-administered measures at a number of antenatal and postnatal study visits. All assessed 629 
phenotypes are described in detail in 34. Here, we give a short outline on the phenotypes which 630 
were used in our analysis. Maternal parity was obtained from the antenatal record; maternal age 631 
was from the date of birth as recorded on the mothers’ national identity document. The mode of 632 
delivery was ascertained by direct observation of the birth by a member of the study team as all 633 
births occurred at Paarl hospital. The SRQ-20 69 is a WHO-endorsed measure of psychological 634 
distress consisting of 20 items which assess non-psychotic symptoms, including symptoms of 635 
depressive and anxiety disorders. Each item is scored according to whether the participant 636 
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responds in the affirmative (scored as 1) or negative (scored as 0) to the presence of a symptom. 637 
Individual items are summed to generate a total score.  The Beck Depression Inventory (BDI-II) 638 
is a widely-used and reliable measure of depressive symptoms 70. The BDI-II comprises 21 639 
items, each of which assesses the severity of a symptom of major depression. Each item is 640 
assessed on a severity scale ranging from 0 (absence of symptoms) to 3 (severe, often with 641 
functional impairment). A total score is then obtained by summing individual item responses, 642 
with a higher score indicative of more severe depressive symptoms.  643 
Smoking was assessed using The Alcohol, Smoking and Substance Involvement Screening Test 644 
(ASSIST) 71, a tool that was developed by the WHO to detect and manage substance use among 645 
people attending primary health care services. The tool assesses substance use and substance-646 
related risk across 10 categories (tobacco, alcohol, cannabis, cocaine, amphetamine-type 647 
stimulants, inhalants, sedatives/sleeping pills, hallucinogens, opioids, and other substances), as 648 
well as enquiring about a history of intravenous drug use. Total scores are obtained for each 649 
substance by summing individual item responses, with a higher score indicative of greater risk 650 
for substance-related health problems.  651 
Hypertension was assessed by blood pressure measured antenatally. 652 
 653 
Genotyping and Imputation                                                                                                                  654 
Genotyping in DCHS was performed using the Illumina PsychArray for those samples with 450k 655 
data, or the Illumina GSA for those samples with EPIC DNA methylation data (Illumina, San 656 
Diego, USA). For both array types, QC and imputation was the same; first, raw data was 657 
imported into Genome Studio and exported into R for QC. SNPs were filtered out if they had a 658 
tenth percentile GC score below 0.2 or an average GC score below 0.1, for a total of 140 SNPs 659 
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removed. Phasing was performed using shapeit, and imputation was performed using impute2 660 
with 1000 Genomes Phase 1 reference data. After imputation, we used qctool to filter out SNPs 661 
with an info score <0.8 or out of Hardy-Weinberg equilibrium. All SNPs with MAF <1% were 662 
removed. 663 
As after imputation, only 5,286 DeepSEA variants were available for those samples genotyped 664 
on the PsychArray and only 4,049 for those samples genotyped on the GSAchip , we performed 665 
LD-pruning based on a threshold of r2 of 0.2 and a window-size of 50 SNPs with an overlap of 5 666 
SNPs. This resulted in 162,292 SNPs (PsychArray) and 176,553 SNPs (GSAchip). 667 
Methylation                                                                                                                           668 
We performed basic quality control on data generated by either the 450k or EPIC arrays using 669 
Illumina’s Genome Studio software for background subtraction and colour correction. Data was 670 
filtered to remove CpGs with high detection p values, those on the X or Y chromosome, or with 671 
previously identified poor performance. 450k data was normalized using SWAN and EPIC data 672 
using BMIQ, and both used ComBat to correct for chip (both), and row (450k only).  Details for 673 
DNA methylation measurements and quality control have been published 62. The final analysis 674 
was performed with 107 samples with methylation levels from the 450k array and 151 with 675 
methylation levels assessed on the EPIC array and available genotypes. Neonatal blood cell 676 
counts were estimated for seven cell types: nucleated red blood cells, granulocytes, monocytes, 677 
natural killer cells, B cells, CD4(+)T cells, and CD8(+)T cells 68. 678 
 679 
VMRs 680 
We identified 6,072 candidate VMRs in DCHS I and 10,005 candidate VMRs in DCHS II. 681 
 682 
The UCI cohort  683 
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Mothers and children were part of an ongoing, longitudinal study, conducted at the University of 684 
California, Irvine (UCI), for which mothers were recruited during the first trimester of pregnancy 685 
31-33. All women had singleton, intrauterine pregnancies. Women were not eligible for study 686 
participation if they met the following criteria: corticosteroids, or illicit drugs during pregnancy 687 
(verified by urinary cotinine and drug toxicology). Exclusion criteria for the newborn were 688 
preterm birth (i.e., less than 34 weeks of gestational age at birth), as well as any congenital, 689 
genetic, or neurologic disorders at birth.  690 
Ethics 691 
The UCI institutional review board approved all study procedures and all participants provided 692 
written informed consent. 693 
Maternal Characteristics 694 
Maternal sociodemographic characteristics (age, parity) were obtained via a standardized 695 
structured interview at the first pregnancy visit. Maternal pre-pregnancy BMI (weight kg/height 696 
m2) was computed based on pre-pregnancy weight abstracted from the medical record, and 697 
maternal height was measured at the research laboratory during the first pregnancy visit. 698 
Obstetric risk conditions during pregnancy, including presence of gestational diabetes and 699 
hypertension, and delivery mode were abstracted from the medical record. At each pregnancy 700 
visit the Center for Epidemiological Studies Depression Scale 59 and the State scale from the 701 
State–Trait Anxiety Inventory 60 were administered. For individuals with <3 missing items on 702 
any scale at any time point, the mean responses for that scale were calculated and then multiplied 703 
by the total number of items in the respective scale, to generate total scale scores that are 704 
comparable to those generated from participants without any missing data. We used the average 705 
depression and anxiety score throughout pregnancy in the calculations. Maternal smoking during 706 
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pregnancy was determined by maternal self-report and verified by measurement of urinary 707 
cotinine concentration. Urinary cotinine was assayed in maternal samples collected at each 708 
trimester using the Nicotine/COT(Cotinine)/Tobacco Drug Test Urine Cassette 709 
(http://www.meditests.com/nicuintescas.html), which involves transferring 4 drops of room 710 
temperature urine into the well of the cassette, and employs a cutoff for COT presence of 711 
200ng/ml. Endorsement of smoking or detection of urinary COT in any trimester was coded as 1, 712 
and absence of evidence for smoking in any trimester coded as 0.  713 
Genotyping 714 
Genomic DNA was extracted from heel prick blood samples and used for all genomic analysis. 715 
Genotyping was performed on Illumina Human Omni Express (24 v1.1) Arrays containing 716 
713,014 SNPs. All samples had a high call rate (above 97%). SNPs with a minor allele frequency  717 
>5% and a p-value for deviation from Hardy-Weinberg-Equilibrium > 1.0 x 10-25 were retained 718 
for analysis. After QC, 602,807 SNPs were available. 719 
Imputation 720 
Before imputation, chromosomal and base pair positions were updated to the Haplotype 721 
Reference Consortium (r1.1) reference set, allele strands were flipped where necessary. Phasing 722 
was performed using EAGLE2 (https://data.broadinstitute.org/alkesgroup/Eagle/) and imputation 723 
was performed using PBWT (https://github.com/VertebrateResequencing/pbwt). Imputed SNPs 724 
with an info score < 0.8, duplicates and ambiguous SNPs were removed resulting in 21,341,980 725 
SNPs. All SNPs with MAF < 0.01 were removed. Of the remaining SNPs, 19,530 were 726 
DeepSEA variants. 727 
DNA Methylation 728 
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DNAm analysis using the Infinium Illumina MethylationEPIC BeadChip (Illumina, Inc., San 729 
Diego, CA) was performed according to the manufacturer´s guidelines in using genomic DNA 730 
derived from neonatal heel prick samples. Quality Control carried out in minfi 61. No outliers 731 
were detected in the median intensities of methylated and unmethylated channels. All samples 732 
had a high call rate of at least 95% and their predicted sex was the same as the phenotypic 733 
sex. We removed CpGs with a high detection value (p<0.0001), probes missing >3 beads in >5% 734 
of the cohort, in addition to non-specific/cross-hybridizing and SNP probes 66,67. Methylation 735 
beta-values were normalized using functional normalization (funnorm) 63. We also iteratively 736 
adjusted the data for relevant technical factors, i.e. array row, experimental batch and sample 737 
plate, using Combat 64.  The final dataset contained 768,910 CpGs. Neonatal blood cell counts 738 
were estimated for seven cell types: nucleated red blood cells, granulocytes, monocytes, natural 739 
killer cells, B cells, CD4(+)T cells, and CD8(+)T cells 68. The final dataset contained 121 740 
samples with available genotypes and methylation values. 741 
VMRs 742 
Applying the same procedure as for  PREDO I and PREDO II, we identified 9,525 candidate 743 
VMRs in the ICU cohort. 744 
 745 
MoBa cohort 746 
Participants represent two subsets of mother-offspring pairs from the national Norwegian Mother 747 
and Child Cohort Study (MoBa) 72. MoBa is a prospective population-based pregnancy cohort 748 
study conducted by the Norwegian Institute of Public Health. The years of birth for MoBa 749 
participants ranged from 1999-2009. MoBa mothers provided written informed consent. Each 750 
subset is referred to here as MoBa1 and MoBa2. MoBa1 is a subset of a larger study within 751 
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MoBa that included a cohort random sample and cases of asthma at age three years 73. We 752 
previously reported an association between maternal smoking during pregnancy and differential 753 
DNA methylation in MoBa1 newborns 74. We subsequently measured DNA methylation in 754 
additional newborns (MoBa2) in the same laboratory (Illumina, San Diego, CA) 11. MoBa2 755 
included cohort random sample plus cases of asthma at age seven years and non-asthmatic 756 
controls. Years of birth were 2002-2004 for children in MoBa1, 2000-2005 for MoBa2.  757 
Ethics 758 
The establishment and data collection in MoBa obtained a license from the Norwegian Data 759 
Inspectorate and approval from The Regional Committee for Medical Research Ethics.  Both 760 
studies were approved by the Regional Committee for Ethics in Medical Research, Norway. In 761 
addition, MoBa1 and MoBa2 were approved by the Institutional Review Board of the National 762 
Institute of Environmental Health Sciences, USA. 763 
Maternal characteristics 764 
To replicate specific GxE and G+E from PREDO I, we focused on those characteristics which 765 
were available in both cohorts: maternal age, pre-pregnancy BMI and hypertension. 766 
Within MoBa, the questionnaires at weeks 17 and 30 include general background information as 767 
well as details on previous and present health problems and exposures. The birth record from the 768 
Medical Birth Registry of Norway 75which includes maternal health during pregnancy as well as 769 
procedures around birth and pregnancy outcomes, is integrated in the MoBa database.  770 
Genotyping and Imputation 771 
DNA was extracted from the MoBa biobank  and genotyped on the Illumina HumanExomeCore 772 
platform. The genotypes were called with GenomeStudio software. Phasing and imputation were 773 
done using shapeit2 (https://mathgen.stats.ox.ac.uk./genetics_software/shapeit/shapeit.html) and 774 
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impute2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) with the thousand genomes 775 
phase 3 reference panel for the European population. Variants with a imputation score of less 776 
than 0.8 and with a minor allele frequency below 1% were filtered out.  777 
Methylation  778 
Details of the DNA methylation measurements and quality control for the MoBa1 participants 779 
were previously described 36 and the same protocol was implemented for the MoBa2 780 
participants. Briefly, at birth, umbilical cord blood samples were collected and frozen at birth at -781 
80°C. All biological material was obtained from the Biobank of the MoBa study 36. Bisulfite 782 
conversion was performed using the EZ-96 DNA Methylation kit (Zymo Research Corporation, 783 
Irvine, CA) and DNA methylation was measured at 485,577 CpGs in cord blood using Illumina’s 784 
Infinium HumanMethylation450 BeadChip 76. Raw intensity (.idat) files were handled in R using 785 
the minfi package to calculate the methylation level at each CpG as the beta-value (β=intensity of 786 
the methylated allele (M)/(intensity of the unmethylated allele (U) + intensity of the methylated 787 
allele (M) + 100)) and the data was exported for quality control and processing. Control probes 788 
(N=65) and probes on X (N=11 230) and Y (N=416) chromosomes were excluded in both 789 
datasets. Remaining CpGs missing > 10% of methylation data were also removed (N=20 in 790 
MoBa1, none in MoBa2). Samples indicated by Illumina to have failed or have an average 791 
detection p value across all probes < 0.05 (N=49 MoBa1, N=35 MoBa2) and samples with 792 
gender mismatch (N=13 MoBa1, N=8 MoBa2) were also removed. For MoBa1 and MoBa2, we 793 
accounted for the two different probe designs by applying the intra-array normalization strategy 794 
Beta Mixture Quantile dilation (BMIQ) 77. The Empirical Bayes method via ComBat was applied 795 
separately in MoBa1 and MoBa2 for batch correction using the sva package in R 65. After quality 796 
control exclusions, the sample sizes were 1,068 for MoBa1 and 685 for MoBa2.   797 
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After QC, the total number of samples was 1,732, with 1,592 overlapping with the methylation 798 
samples. Specific G+E and GxE associations were calculated in the combined dataset of MoBa1 799 
and MoBa2, while VMR analysis was conducted in MoBa1 only. 800 
 801 
Regression analysis 802 
Linear regression analysis was conducted using the lm function in R 3.3.1 (https://www.r-803 
project.org).  We included the child’s sex, gestational age, seven estimated cell counts as well as 804 
the first two (PREDO I and PREDO II), first three (UCI) and first five (DCHS I and II) principal 805 
components of the MDS analysis on the genotypes in the model. The corresponding plot of the 806 
first ten MDS-components in PREDO is depicted in Figure S4. SNP genotypes were recoded 807 
into a count of 0, 1 or 2 representing the number of minor allele copies.  For each VMR site, we 808 
tested SNPs located in a 1MB window up- and downstream of the specific site. In PREDO and 809 
UCI, we restricted the analysis to DeepSEA variants while we used the pruned SNP-set in 810 
DCHS. 811 
For each VMR, we tested four models: 812 
(1) Methylation at tagCpG   ~ covariates + environment 813 
(2) Methylation at tagCpG   ~ covariates + SNP 814 
(3) Methylation at tagCpG   ~ covariates + SNP + environment 815 
(4) Methylation at tagCpG   ~ covariates + SNP + environment + SNP x environment 816 
In model (1) we included all ten different environments, in model (2) all DeepSEA cis SNPs and 817 
in models (3) and (4) all possible environment-cis-SNP combinations. Please also see Figure 1. 818 
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For each model, the AIC, Akaike’s information criterion 37 was calculated and the model with 819 
the lowest AIC was chosen as the best model.  The AIC was obtained using the AIC function in 820 
R 3.3.1 (https://www.r-project.org). 821 
P-values were obtained from the summary function and adjusted for the number of tested Es (E 822 
model), of tested cis SNPs (G model) or of tested cis SNP-environment combinations (G+E/GxE 823 
model) using Bonferroni-correction. Afterwards, we used FDR to correct for all tested tagCpGs 824 
(all models) using p.adjust in R.  825 
 826 
Enrichment analyses 827 
With regard to enrichment for VMRs, CpG-site within VMRs were compared to all other CpG-828 
sites on the 450K array located in non-VMR-regions. With regard to enrichment for VMRs best 829 
explained by G, G+E or GxE, tagCpGs best explained by the specific model were compared to 830 
tagCpGs best explained by any of the other models. For enrichment tests for DeepSEA SNPs, 831 
non-DeepSEA SNPs present in our dataset were used as comparison group. Enrichment tests 832 
were performed based on a hyper-geometric test, i.e. a Fisher-test. The significance levels was 833 
set at p<0.05. 834 
With regard to enrichment for GWAS hits, DeepSEA variants were matched to GWAs variants 835 
based on chromosome and position (hg19). To check for enrichment for nominal significant 836 
GWAS hits, the full summary statistics were derived from the respective publication.  837 
Histone ChiP-seq peaks from Roadmap Epigenomics project for blood and embryonic stem cells 838 
were downloaded from 839 
http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/broadPeak/. 840 
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The pre-processed consolidated broad peaks from the uniform processing pipeline of the 841 
Roadmap project were used.   842 
 843 
Genomic annotation mapping 844 
CpG sites were mapped to the genome location according to Illumina’s annotation using the R-845 
package minfi.   846 
 847 
DeepSEA Analysis 848 
Pretrained DeepSEA model was downloaded from: 849 
http://deepsea.princeton.edu/media/code/deepsea.v0.94.tar.gz and variant files in VCF format are 850 
used for producing e-values. VCF files were first split into smaller files each containing one 851 
million variants and the model was run using the command line on a server with a NVIDIA Titan 852 
X GPU card. 853 
We reran our models using only DeepSEA variants which had been identified by the algorithm 854 
of Zhou and Troyanskaya 38. This method predicts functionality of a SNP based on the DNA-855 
sequence. We included all 212,210 variants with a functional significance e-value below 5x10-05. 856 
The e-values represent the significance of the regulatory impact of given variants compared to 857 
one million random variants.  858 
 859 
Random-effects meta-analysis 860 
GxE and G+E result for PREDO and for MoBa were meta-analysed using a random-effects 861 
model in the R-package rmeta. Replication was defined as DeepSEA-tagCpG-environment 862 
combinations showing the same effect direction in both cohorts, presenting with smaller p-values 863 
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as for PREDO alone and with a FDR-corrected p-value (across all combinations tested in the 864 
meta-analysis) below 0.05. 865 
 866 
Data availability 867 
The datasets analyzed during the current study are not publicly available. However,  868 
an interested researcher can obtain a de-identified dataset after approval from the PREDO Study 869 
Board. Data requests may be subject to further review by the national register authority and by 870 
the ethical committees. Any requests for data use should be addressed to the PREDO Study 871 
Board (predo.study@helsinki.fi) or individual researchers. The summary statistics of the best 872 
models for PREDO I are accessible at: https:/doi.org/10.6084/m9.figshare.8074964. 873 
For access to the UCI cohort, please contact claudia.buss@charite.de , for access to DCHS 874 
please contact Heather.Zar@uct.ac.za, for MoBa access please apply for data access at 875 
https:/www.fih.no  876 
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Figures and figure legends  948 
 949 
Figure 1: Flow diagram of VMR analysis 950 
 951 
Figure 2: VMR-analysis in pruned PREDO I dataset 952 
 953 
A: Percentage of models (G, E, GxE or G+E) with the lowest AIC explaining variable DNA 954 
methylation using the PREDO I dataset with pruned SNPs. 955 
 956 
B: Distribution of the different types of prenatal environment included in the E model with the 957 
lowest AIC (right), in the combinations yielding the best model GxE (middle), or the best model 958 
G+E models (left). To increase readability all counts < 3% have been omitted. 959 
 960 
C: DeltaAIC, i.e , the difference in AIC, between best model and next best model, stratified by 961 
the best model. Y-axis denotes the delta AIC and the X-axis the different models. The median is 962 
depicted by a black line, the rectangle spans the first quartile to the third quartile, whiskers above 963 
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and below the box show the location of minimum and maximum beta-values. P-values are based 964 
on Wilcoxon-tests. 965 
 966 
 967 
Figure 3: VMR-analysis in DeepSEA annotated SNPs in PREDO I dataset. 968 
 969 
A: Percentage of models (G, E, GxE or G+E) with the lowest AIC explaining variable DNA 970 
methylation using the PREDO I dataset with DeepSEA annotated SNPs. 971 
 972 
B: Distribution of the locations of all VMRs and tagVMRs with best model E, G, G+E and GxE 973 
on the 450k array using only DeepSEA variants in relationship to CpG-Islands based on the 974 
Illumina 450K annotation. 975 
 976 
C: Distribution of gene-centric locations of all VMRs and tagVMRs with best model E, G, G+E 977 
and GxE on the 450k array using only DeepSEA variants. 978 
 979 
 980 
Figure 4: Functional annotation of VMR-mapping in DeepSEA annotated SNPs in PREDO I 981 
dataset 982 
 983 
A: Histone mark enrichment for all VMRs. The Y-axis denotes the fold enrichment/depletion as 984 
compared to no-VMRs. Blue bars indicate significant enrichment/depletion, grey bars non-985 
significant differences based on Fisher-tests. 986 
 987 
B: Histone mark enrichment for tagVMRs with best model E, G, G+E and GxE relative to all 988 
VMRs. Green color indicates depletion, red color indicates enrichment. Thick black lines around 989 
the rectangles indicate significant enrichment/depletion based on Fisher-tests. 990 
 991 
C: Histone mark enrichment for all DeepSEA variants in the dataset. Blue bars indicate 992 
significant enrichment/depletion based on Fisher-tests. 993 
 994 
D: Histone mark enrichment for all DeepSEA variants involved in models where either G, G+E 995 
or GxE is the best model as compared to all tested DeepSEA variants. Green color indicates 996 
depletion, red color indicates enrichment. Thick black lines around the rectangles indicate 997 
significant enrichment/depletion based on Fisher-tests. 998 
 999 
 1000 
Figure 5: VMR-analysis in PREDO I and replication datasets 1001 
 1002 
Percentage of models (G, E, GxE or G+E) with the lowest AIC explaining variable DNA 1003 
methylation in PREDO I (450K), DCHS I (450K), PREDO II (EPIC), UCI (EPIC) and DCHS II 1004 
(EPIC) 1005 
 1006 
 1007 
Figure 6: Consistency of best models across cohorts 1008 
 1009 
 
 
44 
Percentage of consistent best models in overlapping tag CpGs of PREDO I (450K), DCHS I 1010 
(450K), PREDO II (EPIC), UCI (EPIC) and DCHS II (EPIC). Overlapping VMRs included 1011 
significantly more CpGs as compared to all VMRs (p<2.2x10-16, Wilcoxon-test, mean=4.43). 1012 
 1013 
 1014 
Figure 7: Enrichment of DeepSEA variants for GWAS associations 1015 
 1016 
A: Enrichment for nominal significant GWAS associations for all tested DeepSEA variants and 1017 
their LD proxies for GWAS for ADHD (attention deficit hyperactivity disorder), ASD (autism 1018 
spectrum disorder), BMI (body-mass index), BP (bipolar disorder), CrossDisorder, IBD 1019 
(inflammatory bowel disease), MDD (major depressive disorder), SCZ (schizophrenia) and T2D 1020 
(Type 2 diabetes). 1021 
The Y-axis denotes the fold enrichment with regard to non-DeepSEAvariants. Blue bars indicate 1022 
significant enrichment/depletion based on Fisher-tests. 1023 
 1024 
B: Enrichment for nominal significant GWAS hits for DeepSEA variants and their LD proxies 1025 
involved in best models with G, G+E or GxE as compared to all tested DeepSEA variants.  1026 
Green color indicates depletion, red color indicates enrichment. Thick black lines around the 1027 
rectangles indicate significant enrichment/depletion based on Fisher-tests. 1028 
 1029 
 1030 
 1031 
 1032 
  1033 
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determine variably methylated regions (VMRs): CpG-sites with MAD-score > 
90th percentile and at least 2 consecutive CpGs with at most 1kb distance  
model E:  
tagCpG ~ environmental 
phenotypes 
 
keep model with lowest AIC across 
all E models 
tagCpG: choose CpG-site with highest MAD-
score within each VMR as representative 
model G:  
tagCpG  ~ cis DeepSEA variants 
 
 
keep model with lowest AIC 
across all G models 
model G+E:  
tagCpG ~ cis DeepSEA 
variants +environmental 
phenotypes  
 
keep model with lowest AIC 
across all G +E models 
model GxE:  
tagCpG ~ cis DeepSEA 
variants x environmental 
phenotypes  
 
keep model with lowest AIC 
across all G x E models 
determine model with lowest AIC across E, G, 
G+E and GxE models as best model for each 
tagCpG 
functional annotation of tagCpGs/DeepSEA 
variants stratified by best model E, G, G+E, GxE 
replication of partition in best model E, G, G+E 
and GxE in independent cohorts 
for each tagCpG 
for all DeepSEA SNPs in 1MB cis  
distance to tagCpGs for ten prenatal E for ten prenatal E x DeepSEA SNPs in 1 MB cis of tag CpG 
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